Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)

Cesare Gridelli, Andrea Camerini, Giovanni Pappagallo, Angelo Pennella, Michele Anzidei, Massimo Bellomi, Roberta Buosi, Rosario Francesco Grasso

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). The aim of this consensus by a panel of experts was to identify important criteria for the selection of patients with NSCLC who would benefit from antiangiogenic therapy. Methods: Radiologists and oncologists were selected for the expert panel. The nominal group technique (NGT) and the Delphi questionnaire were used for consensus generation. The NGT consisted of four steps, the result of which was used to set the Delphi questionnaire. A final report was generated based on the opinions of the experts from the panel. Results: An extremely important prerequisite for the evaluation of an antiangiogenic therapeutic approach in patients with NSCLC was thorough clinical and radiological analysis of the relationships between tumour and vascular or anatomical structures (performed in close co-operation by oncologists and radiologists). The panel identified major parameters to be considered before the use of antiangiogenic treatment, collectively agreeing on the relevance of tumour cavitation, vascular infiltration, endobronchial growth and thromboembolism for chest tumour sites, and of the presence of aneurysms, extra-thoracic bleeding, brain metastases or thrombi for extra-thoracic sites. Moreover, a structured report containing information not only on the tumour but also on the general vascular status is essential to guide the treatment choice The experts agreed that tumour localization in the absence of vessel infiltration, cavitation, and the use of antiplatelet therapy are relevant parameters to be assessed, but their presence should not necessarily exclude a patient from receiving antiangiogenic therapy. Conclusion: Close co-operation between oncologists and radiologists in the diagnosis, treatment selection, and assessment of response is essential for ensuring therapeutic appropriateness in the NSCLC setting. It should be noted that neither the use of antiplatelet therapy nor tumour localisation are to be considered as contraindications to antiangiogenic treatment.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalCancer Imaging
Volume16
Issue number1
DOIs
Publication statusPublished - Dec 28 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Patient Selection
Therapeutics
Blood Vessels
Neoplasms
Thorax
Delphi Technique
Hemorrhage
Thromboembolism
Expert Testimony
Aneurysm
Thrombosis
Neoplasm Metastasis
Safety
Lung
Brain

Keywords

  • Antiangiogenic therapy
  • Clinical features
  • Delphi questionnaire
  • Nominal group technique
  • Non-small cell lung cancer
  • Pulmonary haemorrhage
  • Radiological features

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC). / Gridelli, Cesare; Camerini, Andrea; Pappagallo, Giovanni; Pennella, Angelo; Anzidei, Michele; Bellomi, Massimo; Buosi, Roberta; Grasso, Rosario Francesco.

In: Cancer Imaging, Vol. 16, No. 1, 28.12.2016, p. 1-6.

Research output: Contribution to journalArticle

Gridelli, Cesare ; Camerini, Andrea ; Pappagallo, Giovanni ; Pennella, Angelo ; Anzidei, Michele ; Bellomi, Massimo ; Buosi, Roberta ; Grasso, Rosario Francesco. / Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC). In: Cancer Imaging. 2016 ; Vol. 16, No. 1. pp. 1-6.
@article{14ca6ba961a2430cb45557c7e7f0e3a4,
title = "Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)",
abstract = "Background: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). The aim of this consensus by a panel of experts was to identify important criteria for the selection of patients with NSCLC who would benefit from antiangiogenic therapy. Methods: Radiologists and oncologists were selected for the expert panel. The nominal group technique (NGT) and the Delphi questionnaire were used for consensus generation. The NGT consisted of four steps, the result of which was used to set the Delphi questionnaire. A final report was generated based on the opinions of the experts from the panel. Results: An extremely important prerequisite for the evaluation of an antiangiogenic therapeutic approach in patients with NSCLC was thorough clinical and radiological analysis of the relationships between tumour and vascular or anatomical structures (performed in close co-operation by oncologists and radiologists). The panel identified major parameters to be considered before the use of antiangiogenic treatment, collectively agreeing on the relevance of tumour cavitation, vascular infiltration, endobronchial growth and thromboembolism for chest tumour sites, and of the presence of aneurysms, extra-thoracic bleeding, brain metastases or thrombi for extra-thoracic sites. Moreover, a structured report containing information not only on the tumour but also on the general vascular status is essential to guide the treatment choice The experts agreed that tumour localization in the absence of vessel infiltration, cavitation, and the use of antiplatelet therapy are relevant parameters to be assessed, but their presence should not necessarily exclude a patient from receiving antiangiogenic therapy. Conclusion: Close co-operation between oncologists and radiologists in the diagnosis, treatment selection, and assessment of response is essential for ensuring therapeutic appropriateness in the NSCLC setting. It should be noted that neither the use of antiplatelet therapy nor tumour localisation are to be considered as contraindications to antiangiogenic treatment.",
keywords = "Antiangiogenic therapy, Clinical features, Delphi questionnaire, Nominal group technique, Non-small cell lung cancer, Pulmonary haemorrhage, Radiological features",
author = "Cesare Gridelli and Andrea Camerini and Giovanni Pappagallo and Angelo Pennella and Michele Anzidei and Massimo Bellomi and Roberta Buosi and Grasso, {Rosario Francesco}",
year = "2016",
month = "12",
day = "28",
doi = "10.1186/s40644-016-0102-4",
language = "English",
volume = "16",
pages = "1--6",
journal = "Cancer Imaging",
issn = "1740-5025",
publisher = "e-med",
number = "1",

}

TY - JOUR

T1 - Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)

AU - Gridelli, Cesare

AU - Camerini, Andrea

AU - Pappagallo, Giovanni

AU - Pennella, Angelo

AU - Anzidei, Michele

AU - Bellomi, Massimo

AU - Buosi, Roberta

AU - Grasso, Rosario Francesco

PY - 2016/12/28

Y1 - 2016/12/28

N2 - Background: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). The aim of this consensus by a panel of experts was to identify important criteria for the selection of patients with NSCLC who would benefit from antiangiogenic therapy. Methods: Radiologists and oncologists were selected for the expert panel. The nominal group technique (NGT) and the Delphi questionnaire were used for consensus generation. The NGT consisted of four steps, the result of which was used to set the Delphi questionnaire. A final report was generated based on the opinions of the experts from the panel. Results: An extremely important prerequisite for the evaluation of an antiangiogenic therapeutic approach in patients with NSCLC was thorough clinical and radiological analysis of the relationships between tumour and vascular or anatomical structures (performed in close co-operation by oncologists and radiologists). The panel identified major parameters to be considered before the use of antiangiogenic treatment, collectively agreeing on the relevance of tumour cavitation, vascular infiltration, endobronchial growth and thromboembolism for chest tumour sites, and of the presence of aneurysms, extra-thoracic bleeding, brain metastases or thrombi for extra-thoracic sites. Moreover, a structured report containing information not only on the tumour but also on the general vascular status is essential to guide the treatment choice The experts agreed that tumour localization in the absence of vessel infiltration, cavitation, and the use of antiplatelet therapy are relevant parameters to be assessed, but their presence should not necessarily exclude a patient from receiving antiangiogenic therapy. Conclusion: Close co-operation between oncologists and radiologists in the diagnosis, treatment selection, and assessment of response is essential for ensuring therapeutic appropriateness in the NSCLC setting. It should be noted that neither the use of antiplatelet therapy nor tumour localisation are to be considered as contraindications to antiangiogenic treatment.

AB - Background: The use of antiangiogenic therapy in non-small cell lung cancer (NSCLC) requires thorough evaluation of patient characteristics in order to avoid potential safety issues, particularly pulmonary haemorrhage (PH). The aim of this consensus by a panel of experts was to identify important criteria for the selection of patients with NSCLC who would benefit from antiangiogenic therapy. Methods: Radiologists and oncologists were selected for the expert panel. The nominal group technique (NGT) and the Delphi questionnaire were used for consensus generation. The NGT consisted of four steps, the result of which was used to set the Delphi questionnaire. A final report was generated based on the opinions of the experts from the panel. Results: An extremely important prerequisite for the evaluation of an antiangiogenic therapeutic approach in patients with NSCLC was thorough clinical and radiological analysis of the relationships between tumour and vascular or anatomical structures (performed in close co-operation by oncologists and radiologists). The panel identified major parameters to be considered before the use of antiangiogenic treatment, collectively agreeing on the relevance of tumour cavitation, vascular infiltration, endobronchial growth and thromboembolism for chest tumour sites, and of the presence of aneurysms, extra-thoracic bleeding, brain metastases or thrombi for extra-thoracic sites. Moreover, a structured report containing information not only on the tumour but also on the general vascular status is essential to guide the treatment choice The experts agreed that tumour localization in the absence of vessel infiltration, cavitation, and the use of antiplatelet therapy are relevant parameters to be assessed, but their presence should not necessarily exclude a patient from receiving antiangiogenic therapy. Conclusion: Close co-operation between oncologists and radiologists in the diagnosis, treatment selection, and assessment of response is essential for ensuring therapeutic appropriateness in the NSCLC setting. It should be noted that neither the use of antiplatelet therapy nor tumour localisation are to be considered as contraindications to antiangiogenic treatment.

KW - Antiangiogenic therapy

KW - Clinical features

KW - Delphi questionnaire

KW - Nominal group technique

KW - Non-small cell lung cancer

KW - Pulmonary haemorrhage

KW - Radiological features

UR - http://www.scopus.com/inward/record.url?scp=85007347948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007347948&partnerID=8YFLogxK

U2 - 10.1186/s40644-016-0102-4

DO - 10.1186/s40644-016-0102-4

M3 - Article

AN - SCOPUS:85007347948

VL - 16

SP - 1

EP - 6

JO - Cancer Imaging

JF - Cancer Imaging

SN - 1740-5025

IS - 1

ER -